Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Open-Label Study of the Efficacy and Safety of Imetelstat (GRN163L) in Myelofibrosis and Other Myeloid Malignancies

NCT01731951 is registered in ClinicalTrials.gov with Geron Corporation as lead sponsor.

NCT NCT01731951
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01731951 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Open-Label Study of the Efficacy and Safety of Imetelstat (GRN163L) in Myelofibrosis and Other Myeloid Malignancies
Lead sponsor
Geron Corporation
Phase
Phase 2
Overall status
Completed
Start date
October 29, 2012
Completion date
May 24, 2018
Enrollment
80 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

myeloid malignancies, primary myelofibrosis, secondary myelofibrosis